Dr. Krista Casazza, PhD, RD, LD

Chief Science Officer

Dr. Krista Casazza is a translational scientist whose work bridges metabolism, aging, lysosomal diseases, neurodegeneration, and therapeutic innovation. She previously served as Scientific Director for the Critical Path for Lysosomal Diseases (CPLD) at the Critical Path Institute, where she led regulatory-grade biomarker initiatives to accelerate drug and tool development for rare disorders. Her work integrates regulatory science, multi-stakeholder collaboration, and precision biomarker strategies to advance diagnosis, treatment, and disease monitoring. Dr. Casazza’s earlier academic research explored the metabolic and developmental origins of disease, linking pediatric nutrition, life-course metabolism, and neurodegenerative pathways through shared mechanisms such as impaired autophagy and mitochondrial dysfunction. Building on this foundation, she advises biotechnology and advocacy organizations worldwide on strategies spanning gene and cell therapies, metabolic and aging-related interventions, and clinical development for neurodegenerative and metabolic diseases. Her career reflects a deep commitment to translational science, collaborative innovation, and improving outcomes for individuals affected by rare and complex disorders.